# Patient Health Summary
**Patient:** Doug Langille  
**Location:** Hardwood Lands, Nova Scotia, Canada  
**Last Updated:** January 12, 2026  
**Primary Care:** Dr. Shikhi Phimsharma, Colchester Regional Hospital

---

## Diagnosed Conditions

### Cardiovascular & Metabolic
1. **Hypertension** - Active, under treatment with Telmisartan HCTZ 80/25mg daily
2. **Type 2 Diabetes** - Active, prediabetic progressing toward diabetes
   - HbA1c: 6.9% (Dec 2025) ‚¨ÜÔ∏è from 6.5% (Sept 2025)
   - Fasting glucose: 8.9 mmol/L (significantly elevated)
   - **Treatment:** Metformin ER 1000mg daily + Ozempic 0.25-0.5mg weekly (starting tonight)
   - **Complication:** Early microalbuminuria (urine albumin 22.7 mg/L)
3. **High Cholesterol** - Active, LDL 3.02 mmol/L (target <2.6)
   - **Treatment:** Rosuvastatin 10mg daily

### Other Conditions
4. **Gout** - Active, under prevention with Allopurinol 200mg daily
5. **Low Testosterone (Hypogonadism)** - Under TRT with Testosterone Enanthate 150mg IM every 2 weeks
   - Note: March 2025 showed naturally high testosterone (22.71 vs normal 2.5-10) - likely injection timing
   - To be reviewed with Dr. Massaro Spring 2026
6. **Sleep Apnea** - Active diagnosis (treatment details not in current records)

---

## Current Medications (6 Total)

### Daily Oral Medications (Started Jan 9, 2026)
- **Rosuvastatin** 10mg - Cholesterol
- **Telmisartan HCTZ** 80/25mg - Blood pressure
- **Metformin ER** 1000mg - Blood sugar
- **Allopurinol** 200mg - Gout prevention

### Injectable Medications
- **Ozempic (Semaglutide)** 0.25-0.5mg weekly subcutaneous - Diabetes/weight (FIRST DOSE TONIGHT)
- **Testosterone Enanthate** 150mg IM every 2 weeks - Hormone replacement

---

## Recent Bloodwork Trends (Sept ‚Üí Dec 2025)

### üî¥ Deteriorating (3.5-month period)
- **HbA1c:** 6.5% ‚Üí 6.9% (+0.4%) - Approaching diabetic threshold of 7.0%
- **Urine Albumin:** 7.5 ‚Üí 22.7 mg/L (+203%) - Now above normal, indicating kidney stress
- **Fasting Glucose:** 8.9 mmol/L - Significantly elevated (normal <6.0)

### ‚úÖ Stable/Positive
- **eGFR:** 81 ‚Üí 83 - Excellent kidney filtration
- **Electrolytes:** All normal and stable
- **PSA:** 0.82 - Excellent prostate health
- **Blood Counts:** All normal (March 2025)

---

## Clinical Priorities (January 2026)

### Priority 1: Diabetes Control ‚ö†Ô∏è URGENT
- **Goal:** Reduce HbA1c from 6.9% to <6.0% over next 3-6 months
- **Action:** First Ozempic injection tonight (Jan 12), aggressive lifestyle modification
- **Expected:** HbA1c reduction of 1-2%, weight loss 5-15%

### Priority 2: Monitor Kidney Function
- **Concern:** Microalbuminuria appearing (urine albumin 22.7, normal <20)
- **Action:** Recheck kidney function and urine albumin in 3 months

### Priority 3: Cholesterol Management
- **Goal:** Reduce LDL from 3.02 to <2.6 mmol/L
- **Action:** Rosuvastatin daily, recheck lipids in 3 months

### Priority 4: Blood Pressure Monitoring
- **Action:** Monitor BP on new Telmisartan HCTZ regimen

### Priority 5: Testosterone Review
- **Action:** Revisit with Dr. Massaro Spring 2026 given high natural levels

---

## Next Follow-up

**Recommended:** April 2026 (3 months post-medication initiation)

### Tests Needed:
- HbA1c (assess medication effectiveness)
- Lipid panel (assess statin effectiveness)
- Comprehensive metabolic panel
- Kidney function (eGFR, creatinine)
- Urine albumin/creatinine ratio
- Liver function tests
- Fasting glucose

### Home Monitoring:
- Blood pressure readings
- Weight tracking
- Symptom diary for Ozempic side effects

---

## Health Data Files
- `health_timeline_jan2026.json` - Chronological organization
- `bloodwork_comprehensive_jan2026.json` - Complete lab results
- `medications_jan2026.json` - Current medication details
- `patient_summary_jan2026.json` - This summary (JSON format)
- `patient_summary_jan2026.md` - This summary (Markdown format)

---

**Clinical Note:** The 3.5-month period from September to December 2025 showed significant metabolic deterioration despite no medication intervention, prompting the comprehensive 5-drug regimen initiated January 9, 2026. The addition of Ozempic (starting Jan 12) represents a critical intervention for blood sugar control. Close monitoring over the next 3-6 months is essential to assess treatment effectiveness.
